Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Alphatec Holdings, Inc. has received an average broker rating of "Moderate Buy", with eight buy ratings and one sell rating from analysts.
• Recent target price upgrades include Wells Fargo increasing its estimate from $14 to $16, and Barclays raising theirs from $21 to $22.
• Insider trading activity shows a notable sale of shares by Director Mortimer Berkowitz III, reducing his ownership by 9.18%, while institutional investors now own 66.35% of the company.

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have received an average rating of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $18.25.

ATEC has been the subject of a number of recent research reports. Wells Fargo & Company boosted their target price on Alphatec from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Thursday, October 16th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Weiss Ratings reissued a "sell (d-)" rating on shares of Alphatec in a report on Tuesday, October 14th. JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a research note on Friday. They set an "overweight" rating and a $19.00 price target for the company. Finally, Barclays reissued an "overweight" rating and set a $22.00 price target (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th.

Insiders Place Their Bets

In related news, Director Mortimer Berkowitz III sold 62,500 shares of the company's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $15.97, for a total value of $998,125.00. Following the completion of the sale, the director owned 618,050 shares in the company, valued at approximately $9,870,258.50. This represents a 9.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Craig E. Hunsaker sold 10,876 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the sale, the executive vice president directly owned 1,389,142 shares of the company's stock, valued at approximately $21,295,546.86. This trade represents a 0.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 780,575 shares of company stock valued at $11,769,527 in the last ninety days. 20.90% of the stock is currently owned by insiders.

Institutional Trading of Alphatec

A number of large investors have recently made changes to their positions in ATEC. Wealth Enhancement Advisory Services LLC increased its position in shares of Alphatec by 301.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock valued at $608,000 after buying an additional 45,027 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock worth $133,000 after acquiring an additional 1,552 shares in the last quarter. Western Wealth Management LLC increased its holdings in shares of Alphatec by 9.6% in the first quarter. Western Wealth Management LLC now owns 87,050 shares of the medical technology company's stock worth $883,000 after acquiring an additional 7,614 shares in the last quarter. Lisanti Capital Growth LLC bought a new stake in shares of Alphatec in the first quarter worth about $3,521,000. Finally, Teacher Retirement System of Texas bought a new stake in Alphatec during the 1st quarter worth approximately $158,000. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Performance

Alphatec stock opened at $16.11 on Friday. The stock has a 50-day simple moving average of $15.17 and a 200 day simple moving average of $12.98. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec has a 12-month low of $5.18 and a 12-month high of $16.70. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -14.26 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The company's revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Alphatec will post -1.08 earnings per share for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.